Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of “Hold” by Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been assigned a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $61.60.

Several research analysts have weighed in on the company. Bank of America started coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target for the company. Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday, September 30th. Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $40.00 to $65.00 in a research note on Thursday, October 9th. Finally, Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the transaction, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. This trade represents a 4.67% decrease in their position. The SEC filing for this sale provides additional information. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. State Street Corp raised its position in shares of Supernus Pharmaceuticals by 2.9% in the 2nd quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company’s stock worth $69,614,000 after acquiring an additional 63,210 shares in the last quarter. Geode Capital Management LLC grew its stake in Supernus Pharmaceuticals by 5.5% in the second quarter. Geode Capital Management LLC now owns 1,399,610 shares of the specialty pharmaceutical company’s stock valued at $44,121,000 after purchasing an additional 72,991 shares during the last quarter. Woodline Partners LP lifted its position in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after buying an additional 490,835 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after buying an additional 338,584 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its position in shares of Supernus Pharmaceuticals by 53.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after buying an additional 278,575 shares during the last quarter.

Supernus Pharmaceuticals Stock Down 0.1%

SUPN stock opened at $51.11 on Friday. Supernus Pharmaceuticals has a twelve month low of $29.16 and a twelve month high of $57.65. The stock has a market cap of $2.93 billion, a P/E ratio of -150.32, a PEG ratio of 0.50 and a beta of 0.67. The business’s 50-day moving average price is $47.93 and its 200-day moving average price is $44.34.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The firm had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period last year, the company earned $0.69 earnings per share. On average, equities research analysts expect that Supernus Pharmaceuticals will post 2.38 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.